Viewing Study NCT02588651

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:40 PM
Ignite Modification Date: 2026-02-26 @ 6:52 AM
Study NCT ID: NCT02588651
Status: COMPLETED
Last Update Posted: 2025-11-21
First Post: 2015-10-26
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Sponsor: Deepa Jagadeesh
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None T-cell Lymphoma View
None Angioimmunoblastic T-cell Lymphoma View
None Hepato-splenic T-cell Lymphoma View
None Adult T-cell Leukemia/Lymphoma View
None Enteropathy Associated T-cell Lymphoma View
None NK T-cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lymphoma View
None Leukemia View
None Brentuximab Vedotin View